Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer
- 235 Downloads
The aim of this study was to explore the synergistic anti-tumor effects of cytarabine hyaluronic acid-tyramine (Ara-HA-Tyr) hydrogel conjugates and radiotherapy (RT) in the Lewis lung cancer (LLC) xenograft model, and the mechanisms involved. The radiotherapy sensitization ratio (SER) of 0.5 μg cytarabine (Ara-C) was 1.619 in the LLC cells. Ara-HA-Tyr was prepared by encapsulating Ara-C into hyaluronic acid-tyramine (HA-Tyr) conjugates. The hydrogels were formed through the oxidative coupling of tyramines by hydrogen peroxide (H2O2) and horseradish peroxidase (HRP). Mice engrafted with the LLC cells were given intra-tumoral injections of saline, Ara-C or Ara-HA-Tyr, with or without RT. The combination of Ara-HA-Tyr and RT increased survival compared to free Ara-C and RT (p < 0.05), and prolonged tumor growth delay (TGD). Furthermore, the RT + Ara-HA-Tyr combination therapy significantly reduced 18F-FDG uptake, induced cell cycle arrest at G2/M-phase, increased apoptosis and histone H2AX phosphorylation (γ-H2AX), and decreased the proliferation index (Ki67) in tumor cells compared to either monotherapy. Taken together, Ara-C encapsulated with HA-Tyr effectively sensitized tumor xenografts to RT and showed significantly less systemic toxicity.
KeywordsCytarabine Hydrogel Radiotherapy Synergistic effect
This work was supported by grants from the National Natural Science Foundation of China (No.81201682), the Scientific Research Foundation of the Luzhou Science and Technology Bureau (No.2016LZXNYD-J05), and the Southwest Medical University Foundation (No.201617).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
No studies were conducted on human participants. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All animal experiments were implemented in accordance with the Institutional Animal Care and Use Guidelines, and approved by the Institutional Animal Southwest Medical Care and Use Committee (Luzhou, China).
For this type of study, formal consent is not required.
- 2.Linam J, Yang LX (2015) Recent developments in radiosensitization. Anticancer Res 355:2479–2485Google Scholar
- 7.Spriggs DR, Robbins G, Takvorian T et al (1985) Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study. Cancer Res 458:3932–3936Google Scholar
- 9.Wang J, Wang X, Cao Y, Huang T, Song D‑X, Tao H‑R (2018) Therapeutic potential of hyaluronic acid/chitosan nanoparticles for the delivery of curcuminoid in knee osteoarthritis and an in vitro evaluation in chondrocytes. Int J Mol Med. https://doi.org/10.3892/ijmm.2018.3817
- 10.Lokeshwar VB, Mirza S, Jordan A (2014) Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res 123:35–65. https://doi.org/10.1016/b978-0-12-800092-2.00002-2 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Lawrence TS, Chang EY, Hahn TM et al (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2’,2’-difluoro-2’-deoxycytidine (Gemcitabine). Clin Cancer Res 35:777–782Google Scholar
- 30.Ogawa Y, Kubota K, Ue H et al (2009) Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-radiation therapy for Unresectable carcinomas, type II (KORTUC II). Int J Oncol 343:609–618Google Scholar
- 33.Yoon HY, Koo H, Choi KY, Lee SJ, Kim K, Kwon IC, Leary JF, Park K, Yuk SH, Park JH, Choi K (2012) Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials 3315:3980–3989. https://doi.org/10.1016/j.biomaterials.2012.02.016 CrossRefGoogle Scholar
- 39.Sarkisjan D, van den Berg J, Smit E, Lee YB, Kim DJ, Peters GJ (2016) The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines. Nucleosides Nucleotides Nucleic Acids 3510-12:619–630. https://doi.org/10.1080/15257770.2016.1216565 CrossRefGoogle Scholar
- 40.Heyer WD, Ehmsen KT, Liu J (2010) Regulation of homologous recombination in eukaryotes. Annu Rev Genet 44:113–139. https://doi.org/10.1146/annurev-genet-051710-150955 CrossRefPubMedPubMedCentralGoogle Scholar
- 41.Magin S, Papaioannou M, Saha J, Staudt C, Iliakis G (2015) Inhibition of homologous recombination and promotion of mutagenic repair of DNA double-Strand breaks underpins Arabinoside-nucleoside analogue Radiosensitization. Mol Cancer Ther 146:1424–1433. https://doi.org/10.1158/1535-7163.mct-14-0682 CrossRefGoogle Scholar
- 42.Thiemann M, Oertel S, Ehemann V et al (2012) In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. Radiat Oncol 7:52. https://doi.org/10.1186/1748-717x-7-52 CrossRefPubMedPubMedCentralGoogle Scholar